This document is intended as a resource for clinicians regarding monkeypox virus and special considerations for people living with HIV. The information is compiled from the Centers and Disease Control and Prevention and other sources and will be updated as more information and data become available. Additional resources are available from the IDSA Monkeypox webpage.

Table of Contents

2022 Outbreak
Infection Prevention and Control in Health Care Settings
Diagnosis & Testing
Vaccination
Treatment
Isolation and Prevention Measures for Patients
Guidance for Key Populations
Coverage/Ryan White HIV/AIDS Program Guidance
Acknowledgements

2022 Outbreak

The Centers for Disease Control and Prevention is tracking daily case rates for the U.S. by state and globally. International data collected on people with MPV during the current outbreak indicate that 31% to 50% of people with MPV had HIV. MPV can be transmitted to anyone through close physical contact. The majority of cases in the U.S. and globally to date have occurred among gay, bisexual and other men who have sex with men and are suspected to have occurred through close physical contact. Based on the case data reported to the CDC, Black/African American and Hispanic/Latino individuals have been disproportionately affected by MPV in the U.S. On Aug. 4, U.S. Department of Human Services Secretary Xavier Becerra declared monkeypox a national public health emergency.

Infection Prevention and Control in Health Care Settings

CDC has developed guidance for health care settings to prevent the spread of MPV that includes patient isolation, personal protective equipment, waste management and environmental infection control.

Recommendations include:

- Placing patients in a private room with a dedicated bathroom. Special air handling is not required.
- Ensuring health care workers wear a gown, gloves, eye protection and a NIOSH-approved particulate respirator with N95 folders or higher.
- Performing standard cleaning and disinfection using an EPA-registered hospital-grade disinfectant with an emerging viral pathogen claim.
- Handling soiled laundry with standard procedures, avoiding contact with any lesion material. Laundry should be gently contained in a bag without dispersing any infectious material.
- Avoiding dry dusting, sweeping or vacuuming in the room.
• Monitoring health care personnel and patients with an exposure to MPV and providing postexposure management according to the [CDC Monitoring People Who Have Been Exposed](https://www.cdc.gov/mpv/about/exposure.html) guidance.
• Discontinuing patient isolation in consultation with your state or local health department.

**Diagnosis & Testing**

• CDC [recommends](https://www.cdc.gov/mpv/about/testing.html) that providers consider testing for all rashes with clinical suspicion of having MPV in addition to testing for sexually transmitted infections and other potential causes of the rash. (See also [What to Do If You Suspect Monkeypox](https://www.cdc.gov/mpv/about/testing.html).)
• The clinical presentation of MPV is different than other outbreaks. CDC has [developed guidance](https://www.cdc.gov/mpv/about/testing.html) with photos to help with recognizing MPV (see below).
• Also see [A Web-Scraped Image Database of Monkeypox, Chickenpox, Smallpox, Cowpox and Measles](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042428/), Islam et al., *Nature* 2022.

### Key Characteristics for Identifying Monkeypox From the CDC Clinical Recognition Webpage

- Lesions are well circumscribed, deep seated, and often develop umbilication (resembles a dot on the top of the lesion)
- Lesions are relatively the same size and same stage of development on a single site of the body (ex: pustules on face or vesicles on legs)
- Fever before rash
- Lymphadenopathy common
- Disseminated rash is centrifugal (more lesions on extremities, face)
- Lesions on palms, soles
- Lesions are often described as painful until the healing phase when they become itchy (crusts)

**Examples of Monkeypox Rashes**

Photo credit: UK Health Security Agency

- Testing is available from your [health department](https://www.cdc.gov/mpv/about/testing.html) through the public health Laboratory Response Network or through the following commercial laboratories:
- Aegis Sciences;
- Mayo Laboratories;
- Labcorp;
- Quest Diagnostics;
- Sonic Healthcare USA.

- CDC recommends collecting two swabs from two to three lesions (See CDC collection guidance). State and commercial laboratory protocols and swab requirements vary. Check with your state health department for its protocols.
- Testing conducted by health departments is available at no cost. Patients will be charged for testing conducted by the commercial laboratories and the fees will vary. For insured patients, their health insurer will be billed, but they may be subject to their health plan’s cost sharing requirement. Uninsured patients will be required to pay out of pocket for testing.

**Vaccination**

**Vaccines**

- CDC recommends vaccination within four days of exposure to MPV to prevent disease, but within up to 14 days may be beneficial.
- The preferred vaccine JYNNEOS is currently in short supply in the U.S. and is being distributed by the federal government to state and territorial health departments based on case data and size of the population at high risk in a jurisdiction.
- JYNNEOS is a two-dose vaccine licensed by the U.S. Food and Drug Administration for prevention of smallpox and MPV. The FDA recommendation is for the two doses to be administered 28 days apart.
- The JYNNEOS vaccine has been studied in people with HIV and people with AIDS (CD4 > 100 cells/mm³). Available data indicate the vaccine is safe for people with HIV and that people with HIV generated an immune response comparable to people without HIV. (see CDC HIV MPV guidance).
- Under the public health emergency declaration, FDA granted an emergency use authorization to allow for intradermal administration of JYNNEOS with an injection volume of 0.1 mL for people 18 years and older. (see CDC Interim JYNNEOS Guidance).
- ACAM2000 is a one-dose vaccine that contains live virus. A greater supply of ACAM2000 is available through the Strategic National Stockpile. This vaccine may cause severe illness in people with HIV and other individuals who are immunocompromised.
- ACAM2000 is a live virus vaccine and should not be given to people with HIV (see CDC HIV MPV guidance).
- The CDC recommends against delaying MPV vaccination following COVID-19 vaccination.
- After MPV vaccination, a 4-week waiting period could be considered particularly for young men (ages 12 to 39) before receiving a Moderna, Novavax, or Pfizer-BioNTech COVID-19 vaccine because of the risk for myocarditis and pericarditis. This also could be considered for the Moderna and Pfizer-BioNTech COVID-19 bivalent boosters.

**Access**

- State and territorial health departments are determining the allocations and eligibility policies for vaccination within their state/jurisdiction.
- For states and jurisdictions using online or telephone registration programs, we recommend reserving appointments or vaccine doses for safety-net clinics serving populations at higher risk, including sexual and gender minorities, people of color, people with HIV and other populations at risk for severe illness.
Treatment

- Tecovirimat (TPOXX) is approved by FDA for the treatment of smallpox under the “Animal Rule” because clinical trials were not ethical or feasible since it has a high fatality rate and has been eradicated.
- CDC currently recommends treatment for people with severe disease or people who may be at high risk for severe disease, including people with HIV who are immunocompromised. It is uncertain whether treating mild disease in people who are not immunocompromised is beneficial.
- The AIDS Clinical Trials Group is conducting the Study of Tecovirimat for Human Monkeypox Virus (STOMP) Clinical Trial (A5418) to evaluate the effectiveness of TPOXX. See the STOMP website for a list of participating clinical trial sites.
- TPOXX for treatment of MPV is only available through a CDC expanded access investigation new drug protocol.¹
- TPOXX can be requested through your state or territorial health department or by contacting the CDC Emergency Operations Center (770-488-7100; poxvirus@cdc.gov). Assistance from the CDC Operations Center is available 24/7, including weekends.
- CDC and FDA allow for treatment to be started before the paperwork is submitted with the completion of an informed consent form (Spanish version) and before confirmatory testing results are available. State policies may vary.
- Jurisdictions are encouraged to allow treating facilities to preposition a limited supply of TPOXX inventory to expedite access and prevent delays after hours or on weekends.
- TPOXX has been purchased by the federal government for the Strategic National Stockpile so it is available at no charge to clinics, institutions and patients.
- Severe pain has been a common morbidity with this outbreak. Pain management should be prioritized as part of the treatment plan, and CDC has developed guidance for managing pain in patients with MPV.

Considerations for Treating People With HIV From CDC:

- Patients with HIV who have low CD4 cell count or who are not on treatment may be at increased risk for severe illness from MPV.
- Vaccination, medication, treatment and close monitoring are recommended for patients with HIV who are exposed to or suspected to have MPV.
- Patients with HIV on treatment for MPV should continue their antiretroviral treatment without interruption.
- The HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Drug-Drug Interactions tables have been updated to include an Antivirals – Orthopoxviruses (Monkeypox, Smallpox) section. Dose adjustments are not recommended for any of the antiretrovirals when treating people with HIV with TPOXX.
- The HHS Guidelines recommend delaying initiation of cabotegravir/rilpivirine (Cabenuva) during tecovirimat treatment and for two weeks after completing treatment.
- Clinicians also can consult the Liverpool HIV drug interactions page for clinically relevant drug interactions and may offer additional considerations to the HHS Guidelines as more information is learned.
- Patients taking pre-exposure prophylaxis or postexposure prophylaxis should continue without interruption.

• Patients with HIV and MPV who are not on HIV treatment should initiate antiretroviral treatment as soon as possible.

Isolation and Prevention Measures for Patients

• CDC has developed guidance for safer sex to prevent the spread of MPV, such as limiting the number of sex partners, covering and avoiding contact with any rashes and avoiding anonymous partners, and for large gatherings, such as avoiding skin-to-skin contact and dark places such as back rooms, saunas or sex clubs.
• CDC recommends that people with MPV isolate until all symptoms resolve, which typically is between two and four weeks after onset of symptoms.
• CDC also offers guidance for people with MPV who may not be able to isolate for the duration of the illness.
• For the 2022 global outbreak, in the United States, the primary type of exposure and transmission has been skin-to-skin contact and/or close intimate contact with individuals with MPV.
• It is not yet known how often, or at what point during infection, the virus may be spread from respiratory secretions or whether the virus can be spread through bodily fluids, such as semen and vaginal fluids.

Guidance for Key Populations

CDC has developed the guidance documents below for people with HIV, children and adolescents and people who are pregnant or breastfeeding.

Clinical Considerations for Treatment and Prophylaxis of Monkeypox Virus Infection in People With HIV

• Special considerations for treating and vaccinating people with HIV developed because people with HIV with advanced disease may be at increased risk for severe disease.

Clinical Considerations for Monkeypox in Children and Adolescents (CDC)

• Guidance based on available data and information on conditions that may put children and adolescents less than 18 years of age at greater risk for severe illness in addition to considerations for treating and vaccinating them.

Clinical Considerations for Monkeypox in People Who Are Pregnant or Breastfeeding (CDC)

• Guidance based on available data and information on risks for pregnant and breastfeeding people and vaccination, treatment and diagnosis of people who are pregnant and breastfeeding.

Access to Services and Coverage

CDC-recommended vaccinations and antiviral treatments are available for people exposed to monkeypox or diagnosed with monkeypox virus infection. Monkeypox vaccines and treatment are currently being provided by the U.S. federal government without any charge to providers or patients.

Ryan White HIV/AIDS Program

HRSA’s HIV/AIDS Bureau Associate Administrator Laura Cheever, MD, MPH, issued a “Dear Colleague” letter with guidance for Ryan White program providers on monkeypox. Key points are highlighted below.
• MPV testing is available through public health laboratories and commercial laboratories. Testing done through public health laboratories is free of charge, while commercial laboratories bill health care coverage for the cost of the test. If a RWHAP provider does not have access to public health laboratory testing, RWHAP funds can be used to cover co-pays and deductibles for testing for clients with health insurance and for the cost of testing for clients without insurance.

• RWHAP funds may be used to pay for fees associated with vaccine administration and treatment of monkeypox for eligible clients, such as medical visit costs, including personal protective equipment for staff, and vaccination supplies, including co-pays and deductibles for insured clients, in accordance with Policy Clarification Notice #16-02 Ryan White HIV/AIDS Program Services: Eligible Individuals & Allowable Uses of Funds.

• The MPV-related services available at Ryan White clinics will vary depending on the resources available locally. A directory of Ryan White providers is available online.

Acknowledgements: Thank you to the following HIVMA members for their contributions to, and review of, this brief: Wendy Armstrong, MD, FIDSA (Emory University), Marwan Haddad, MD, MPH (Community Health Center Inc.), Ellen Kitchell, MD (UT Southwestern) and Rajesh Gandhi, MD, FIDSA (Massachusetts General Hospital).